| Authors: |
Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Tyshevich A; BostonGene Corporation, Waltham, Massachusetts., Shavronskaya D; BostonGene Corporation, Waltham, Massachusetts., Alesse J; BostonGene Corporation, Waltham, Massachusetts., English N; BostonGene Corporation, Waltham, Massachusetts., Sheehan E; BostonGene Corporation, Waltham, Massachusetts., Syzrantsev N; BostonGene Corporation, Waltham, Massachusetts., Nesmelov A; BostonGene Corporation, Waltham, Massachusetts., Zhuang TZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ahmed S; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Henderson J; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Dent K; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., McChesney E; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas., Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas. |
